Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.56 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1979259 | 0.87 | PABPC1 (0.62) | LMNAHTTALDH1A1ATMPABPC1 | |
| SCHEMBL12065 | 0.87 | SMN1; SMN2 (0.62) | SMN1; SMN2LMNAHTTALDH1A1KDM4E | |
| SCHEMBL12597606 | 0.87 | KMT2A (0.70) | SMN1; SMN2LMNAHTTALDH1A1HCRTR1 | |
| SCHEMBL1978682 | 0.86 | PABPC1 (0.59) | HTTALDH1A1ATMPABPC1HCRTR1 | |
| SCHEMBL12198 | 0.86 | SMN1; SMN2 (0.65) | SMN1; SMN2LMNAHTTALDH1A1KDM4E | |
| SCHEMBL12598027 | 0.86 | PABPC1 (0.61) | HTTALDH1A1ATMPABPC1HCRTR1 | |
| SCHEMBL12241 | 0.86 | PABPC1 (0.61) | LMNAHTTALDH1A1ATMPABPC1 | |
| SCHEMBL1981183 | 0.85 | PABPC1 (0.60) | LMNAALDH1A1ATMPABPC1KMT2A | |
| SCHEMBL1979594 | 0.85 | PABPC1 (0.62) | SMN1; SMN2LMNAALDH1A1ATMPABPC1 | |
| SCHEMBL1982153 | 0.85 | PABPC1 (0.52) | SMN1; SMN2LMNAHTTALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240071588-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | SERVIER PHARMACEUTICALS LLC (US) | 2024-02-29 | — | — | US | disclosed |
| EP-3561077-B1 | METHODS FOR CELL-PROLIFERATION-RELATED DISORDERS | SERVIER LAB (FR) | 2022-12-21 | — | — | EP | disclosed |
| US-20200281501-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | SERVIER PHARMACEUTICALS LLC | 2020-09-10 | — | — | US | disclosed |
| US-10711314-B2 | Methods for diagnosing IDH-mutant cell proliferation disorders | AGIOS PHARMACEUTICALS, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-10610125-B2 | Methods and compositions for cell-proliferation-related disorders | AGIOS PHARMACEUTICALS, INC. (US) | 2020-04-07 | — | — | US | disclosed |
| EP-3561077-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | Agios Pharmaceuticals, Inc. (US) | 2019-10-30 | — | — | EP | disclosed |
| US-20190276894-A1 | METHOD FOR TREATING CELL PROLIFERATION RELATED DISORDERS | SERVIER PHARMACEUTICALS LLC | 2019-09-12 | — | — | US | disclosed |
| EP-2406389-B1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | AGIOS PHARMACEUTICALS INC (US) | 2019-05-08 | — | — | EP | disclosed |
| US-9982309-B2 | Method for treating cell proliferation related disorders | AGIOS PHARMACEUTICALS, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20170325708-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | AGIOS PHARMACEUTICALS, INC. (US) | 2017-11-16 | — | — | US | disclosed |
| US-20130183281-A1 | METHODS AND COMPOSITONS FOR CELL-PROLIFERATION-RELATED DISORDERS | SERVIER PHARMACEUTICALS LLC | 2013-07-18 | — | — | US | disclosed |
| US-20130035329-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2013-02-07 | — | — | US | disclosed |
| US-20130035329-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2013-02-07 | — | — | US | disclosed |
| US-20130035329-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2013-02-07 | — | — | US | disclosed |
| EP-2509600-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER CHARACTERIZED AS HAVING AN IDH MUTATION | Agios Pharmaceuticals, Inc. (US) | 2012-10-17 | — | — | EP | disclosed |
| US-20120121515-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | SERVIER PHARMACEUTICALS LLC | 2012-05-17 | — | — | US | disclosed |
| WO-2011072174-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER CHARACTERIZED AS HAVING AN IDH MUTATION | AGIOS PHARMACEUTICALS, INC. (US) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011072174-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER CHARACTERIZED AS HAVING AN IDH MUTATION | AGIOS PHARMACEUTICALS, INC. (US) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011050210-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | AGIOS PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| WO-2010105243-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | AGIOS PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10711314-B2 | Methods for diagnosing IDH-mutant cell proliferation disorders | MKI67, IDH1, IDH3A | SMN1; SMN2 771/4885LMNA 3404/4885HTT 249/4885 |
| US-10610125-B2 | Methods and compositions for cell-proliferation-related disorders | MKI67, BRCA1, CLN6 | SMN1; SMN2 18/4885LMNA 708/4885HTT 541/4885 |
| US-20170325708-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | MKI67, BRCA1, CLN6 | SMN1; SMN2 18/4885LMNA 708/4885HTT 541/4885 |
| US-20120121515-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | MKI67, BRCA1, CLN6 | SMN1; SMN2 18/4885LMNA 708/4885HTT 541/4885 |
| US-20240071588-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | MKI67, BRCA1, CLN6 | SMN1; SMN2 18/4885LMNA 708/4885HTT 541/4885 |
| US-20130183281-A1 | METHODS AND COMPOSITONS FOR CELL-PROLIFERATION-RELATED DISORDERS | IDH2, IDH1, MKI67 | SMN1; SMN2 234/4885LMNA 1485/4885HTT 20/4885 |
| US-20130035329-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | MCL1, TP53, CD44 | SMN1; SMN2 474/4885LMNA 1011/4885HTT 2447/4885 |
| US-20200281501-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | MKI67, BRCA1, CLN6 | SMN1; SMN2 18/4885LMNA 708/4885HTT 541/4885 |
| US-20190276894-A1 | METHOD FOR TREATING CELL PROLIFERATION RELATED DISORDERS | IDH2, IDH1, IDH3A | SMN1; SMN2 15/4885LMNA 1683/4885HTT 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.